Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

I occasionally try to ask a question that provides the opportunity for better arguments but it usually goes nowhere (except to question my motives). Maybe this one will offer you such an opportunity. The paper is from 1990 and the excerpt is from the section entitled GI PHYSIOLOGICAL CONSTRAINTS IN ORAL CONTROLLED DRUG DELIVERY METHODOLOGY:
"The residence time in the small intestine may generally vary from 2 to 4 h prior to arrival in the colon. Transit through the colon is highly significant in terms of controlled release products and drug absorption. It varies from a few hours to 2 days, depending on parameters such as the nature of the ingested nutrient (high or low content of dietary fibers), age, and disease state."

Obviously the 30 year old article is directly relevant to the current issue. If you could explain how BDD and IPIX will be able to direct Brilacidin to the specific area of inflammation in various colitis patients when the OralogiK release system is time based (versus ph based), given the significant variations in transit time in the colon from patient to patient, it might serve as one of those missing better arguments that you could pound the table about. I, for one, don't understand it.

https://onlinelibrary.wiley.com/doi/pdf/10.1002/bdd.2510110602
p.466

BTW, the current trial is in healthy patients so "disease state" won't affect results and the 9 patients aren't likely to provide statistical significance to the effect of the issue of age as it effects transit time and dispersal of the drug.

Results are due SOON. What outcomes would you describe as successful enough to justify pounding the table?
https://clinicaltrials.gov/ct2/show/NCT04240223?term=EXPAND%5BConcept%5D+%22innovation+pharmaceuticals%22&draw=2&rank=1